| |
| |
|
| Insider
Information: |
Daniell Richard |
| Relationship: |
|
| City: |
Petach Tikva |
| State: |
L3 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
98,943 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,366,403 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
98,943 |
|
|
| Total
Value |
$1,366,403 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Teva Pharmaceutical Industries L... |
TEVA |
|
2024-03-05 |
98,943 |
2018-03-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2024-03-05 |
4 |
AS |
$13.52 |
$657,240 |
D/D |
(48,629) |
98,943 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2024-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
77,802 |
124,996 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2024-03-04 |
4 |
AS |
$13.34 |
$1,277,207 |
D/D |
(95,762) |
69,770 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2024-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,512 |
103,282 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2024-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
62,250 |
132,020 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2024-02-28 |
4 |
AS |
$13.12 |
$270,176 |
D/D |
(20,599) |
69,770 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2024-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,599 |
90,369 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2023-03-07 |
4 |
AS |
$9.43 |
$509,173 |
D/D |
(54,007) |
69,770 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2023-03-06 |
4 |
AS |
$9.93 |
$178,776 |
D/D |
(18,002) |
123,777 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2023-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,576 |
141,779 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2023-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
49,433 |
119,203 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2023-02-28 |
4 |
AS |
$9.89 |
$437,502 |
D/D |
(44,252) |
69,770 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2023-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
70,840 |
93,424 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2022-03-07 |
4 |
AS |
$7.37 |
$166,311 |
D/D |
(22,576) |
43,182 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2022-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,576 |
65,758 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2022-03-04 |
4 |
AS |
$7.48 |
$272,183 |
D/D |
(36,376) |
43,182 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2022-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
59,278 |
63,638 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2022-02-28 |
4 |
AS |
$8.14 |
$167,713 |
D/D |
(20,598) |
20,280 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,598 |
40,878 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2022-02-09 |
4 |
AS |
$9.06 |
$119,010 |
D/D |
(13,135) |
20,280 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,135 |
33,415 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2021-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,920 |
27,793 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2021-03-04 |
4 |
AS |
$10.58 |
$79,521 |
D/D |
(7,513) |
20,280 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2021-03-03 |
4 |
AS |
$10.88 |
$10,803 |
D/D |
(993) |
11,873 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Exec. VP, European Commercial |
• – – |
2021-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,101 |
12,866 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
